January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors.
Mr. Green joined the MAPS board in December 2020 and — among other things — raised key funds and laid critical groundwork for MAPS Public Benefit Corporation’s evolution, first into Lykos Therapeutics and then into Resilient Pharmaceuticals. He will continue as a volunteer on the board’s 40th Anniversary Committee, supporting MAPS in celebrating its milestone anniversary in 2026.
Ms. Volat, a champion for and model of collaborative leadership across the field who joined the MAPS board in August 2019, offered key insight to inform the organization’s future strategy and was a key figure in MAPS’ recent transition in executive leadership. She will continue to support the board by participating as a volunteer on the Nominations Committee to search for her and Mr. Green’s replacements.
MAPS is grateful for Joe and Miriam’s time, dedication, and thoughtfulness in their service to our mission, and looks forward to working together in the future.
Miriam and Joe have each dedicated their time and talents to MAPS — and the psychedelic ecosystem — through difficult, dynamic challenges. We are deeply grateful for their years-long dedication to our shared mission and community, as well as their continued dedication to MAPS’ future, as volunteers on Board committees. I wish them both the best, Joe as he deepens his work with his synagogue and Miriam as she dedicates energy towards ensuring Indigenous medicines and biocultures are protected for the long-term.
— Rick Doblin, PhD; Founder & President, MAPS
###
ABOUT MAPS
Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS previously sponsored the most advanced psychedelic-assisted therapy research in the world and continues to support psychedelic and marijuana research with a focus on the people and places most impacted by trauma. MAPS incubated Lykos Therapeutics (now named Resilient), a drug-development public benefit company, and The Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance psychedelic research, change drug policy, and shape culture.